{"id":798521,"date":"2025-01-07T09:12:54","date_gmt":"2025-01-07T14:12:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/"},"modified":"2025-01-07T09:12:54","modified_gmt":"2025-01-07T14:12:54","slug":"lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/","title":{"rendered":"Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Company Believes it is Well Positioned for Mid-Term and Long-Term Growth as<br \/><\/em><br \/>\n        <em>Current Capacity Continues to Support up to $300 Million in Annual Revenue<\/em>\n      <\/p>\n<p align=\"justify\">CHASKA, Minn., Jan.  07, 2025  (GLOBE NEWSWIRE) &#8212; \u00a0Lifecore Biomedical, Inc. (NASDAQ: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oj7ONvKxdT23YqPgnhJPTOEZGjnSwarlyMoANwTBm5tM0TajsjPC1vj4uVyVc3vPoiMVIfKnHCcXKTLG6AfPt4IAFqxiNFwlFLcSIS7LNOo=\" rel=\"nofollow\" target=\"_blank\">LFCR<\/a>) (\u201cLifecore\u201d), a fully integrated contract development and manufacturing organization (\u201cCDMO\u201d), today announced that it has entered into a sales agreement with a non-competitive buyer for the company\u2019s previously purchased, but not yet installed, high-speed, multi-purpose 10-head isolator filler. Under the terms of the agreement, the buyer will pay Lifecore an aggregate purchase price of $17 million in exchange for the 10-head filler. Lifecore received $7 million at closing and anticipates receiving the remaining payments in three tranches over the next 18 months.<\/p>\n<p align=\"justify\">\u201cAs we continue to execute our growth strategy, we have continued to carefully examine all aspects of the business to identify opportunities for right-sizing and efficiency,\u201d said Ryan Lake, chief financial officer of Lifecore. \u201cWith the recent installation of our high-speed 5-head filler, we have built $300 million of revenue-generating capacity to support our mid-term and long-term revenue growth objectives. Accordingly, we felt that the sale of the 10-head filler, which we believe represented excess capital equipment, represented a compelling opportunity to monetize unused equipment and enhance our financial position. Moving forward, we intend to continue to carefully evaluate equipment expenditures to ensure that future capital investments are aligned with projected operational needs.\u201d<\/p>\n<p align=\"justify\">In September, Lifecore announced that it had successfully installed and qualified a new high-speed, multi-purpose 5-head isolator filler, doubling the available capacity it has to offer existing and future customers. With the 5-head filler GMP-ready, the company is engaging in discussions with customers to take advantage of the speed and aseptic isolation benefits of this state-of-the-art, multi-container filler.<\/p>\n<p align=\"justify\">\n        <strong>About Lifecore Biomedical <\/strong>\n      <\/p>\n<p align=\"justify\">Lifecore Biomedical, Inc. (Nasdaq: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oj7ONvKxdT23YqPgnhJPTOaKN7jjrkd_RjA0QRo6VeT_sNrJWqgLqTW7Nn-XOGIjjWPfoeBb9YkDVUHfMf3vB8CSJvQgZD4FHNVs7ImODbo=\" rel=\"nofollow\" target=\"_blank\">LFCR<\/a>) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore\u2019s website at <u>www.lifecore.com<\/u>.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Important Cautions Regarding Forward-Looking Statements<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as \u201canticipate\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cproject\u201d, \u201cplan\u201d, \u201cintend\u201d, \u201cbelieve\u201d, \u201cmay\u201d, \u201cmight\u201d, \u201cwill\u201d, \u201cshould\u201d, \u201ccan have\u201d, \u201clikely\u201d and similar expressions are used to identify forward-looking statements. In addition, all statements regarding our anticipated future operating and financial expectations and opportunities, customer opportunities and relationships are forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, as the company\u2019s ability to successfully enact its business strategies, including with respect to installation, capacity generation and its ability to attract demand for its services, and its ability expand its relationship with its existing customers or attract new customers; the impact of inflation on Lifecore\u2019s business and financial condition; the receipt of payments required by the sales agreement; changes in business conditions and general economic conditions both domestically and globally, including rising interest rates and fluctuation in foreign currency exchange rates; Lifecore\u2019s ability to access sufficient capital to fund its business strategies; and other risk factors set forth from time to time in Lifecore\u2019s SEC filings, including, but not limited to, the Annual Report on Form 10-K for the year ended May 26, 2024 (the \u201c2024 10-K\u201d). For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the Securities and Exchange Commission, including the risk factors contained in the 2024 10-K. Forward-looking statements represent management\u2019s current expectations as of the date hereof and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.<\/em>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzYzMCM2NjgxNzk1IzIwMDc3NTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTRhNTAxMDMtNGNkZi00ODMwLTg0NTQtNDY0OTc1NDJkOGFjLTEwMTkzMjk=\/tiny\/Lifecore-Biomedical-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Lifecore Biomedical, Inc. Contact Information:\r\n\r\nVida Strategic Partners\r\nStephanie Diaz (Investors)\r\n415-675-7401\r\nsdiaz@vidasp.com\r\n\r\nTim Brons (Media)\r\n415-675-7402\r\ntbrons@vidasp.com\r\n\r\nRyan D. Lake (CFO)\r\nLifecore Biomedical\r\n952-368-6244\r\nryan.lake@lifecore.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company Believes it is Well Positioned for Mid-Term and Long-Term Growth as Current Capacity Continues to Support up to $300 Million in Annual Revenue CHASKA, Minn., Jan. 07, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Lifecore Biomedical, Inc. (NASDAQ: LFCR) (\u201cLifecore\u201d), a fully integrated contract development and manufacturing organization (\u201cCDMO\u201d), today announced that it has entered into a sales agreement with a non-competitive buyer for the company\u2019s previously purchased, but not yet installed, high-speed, multi-purpose 10-head isolator filler. Under the terms of the agreement, the buyer will pay Lifecore an aggregate purchase price of $17 million in exchange for the 10-head filler. Lifecore received $7 million at closing and anticipates receiving the remaining payments in three tranches over the next 18 months. \u201cAs &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798521","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company Believes it is Well Positioned for Mid-Term and Long-Term Growth as Current Capacity Continues to Support up to $300 Million in Annual Revenue CHASKA, Minn., Jan. 07, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Lifecore Biomedical, Inc. (NASDAQ: LFCR) (\u201cLifecore\u201d), a fully integrated contract development and manufacturing organization (\u201cCDMO\u201d), today announced that it has entered into a sales agreement with a non-competitive buyer for the company\u2019s previously purchased, but not yet installed, high-speed, multi-purpose 10-head isolator filler. Under the terms of the agreement, the buyer will pay Lifecore an aggregate purchase price of $17 million in exchange for the 10-head filler. Lifecore received $7 million at closing and anticipates receiving the remaining payments in three tranches over the next 18 months. \u201cAs &hellip; Continue reading &quot;Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-07T14:12:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzYzMCM2NjgxNzk1IzIwMDc3NTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million\",\"datePublished\":\"2025-01-07T14:12:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\\\/\"},\"wordCount\":716,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzYzMCM2NjgxNzk1IzIwMDc3NTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\\\/\",\"name\":\"Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzYzMCM2NjgxNzk1IzIwMDc3NTY=\",\"datePublished\":\"2025-01-07T14:12:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzYzMCM2NjgxNzk1IzIwMDc3NTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzYzMCM2NjgxNzk1IzIwMDc3NTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/","og_locale":"en_US","og_type":"article","og_title":"Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million - Market Newsdesk","og_description":"Company Believes it is Well Positioned for Mid-Term and Long-Term Growth as Current Capacity Continues to Support up to $300 Million in Annual Revenue CHASKA, Minn., Jan. 07, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Lifecore Biomedical, Inc. (NASDAQ: LFCR) (\u201cLifecore\u201d), a fully integrated contract development and manufacturing organization (\u201cCDMO\u201d), today announced that it has entered into a sales agreement with a non-competitive buyer for the company\u2019s previously purchased, but not yet installed, high-speed, multi-purpose 10-head isolator filler. Under the terms of the agreement, the buyer will pay Lifecore an aggregate purchase price of $17 million in exchange for the 10-head filler. Lifecore received $7 million at closing and anticipates receiving the remaining payments in three tranches over the next 18 months. \u201cAs &hellip; Continue reading \"Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-07T14:12:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzYzMCM2NjgxNzk1IzIwMDc3NTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million","datePublished":"2025-01-07T14:12:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/"},"wordCount":716,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzYzMCM2NjgxNzk1IzIwMDc3NTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/","name":"Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzYzMCM2NjgxNzk1IzIwMDc3NTY=","datePublished":"2025-01-07T14:12:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzYzMCM2NjgxNzk1IzIwMDc3NTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzYzMCM2NjgxNzk1IzIwMDc3NTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital-equipment-for-17-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798521"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798521\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}